BrightEdge is the American Cancer Society’s donor-funded, philanthropic venture capital fund. The fund invests in for-profit companies developing novel cancer-focused treatments. BrightEdge’s goal is to accelerate commercialization of innovative oncology treatments through capital investment, market awareness, and a shared commitment to eradicate cancer.